Fertility Preservation in Endometrial and Ovarian Cancer: Evidence, Challenges and Emerging Approaches

Fertility preservation is increasingly relevant for reproductive-aged patients with endometrial or ovarian cancer, but oncological safety must remain the primary objective. This review summarizes current oncological and reproductive outcomes, identifies limitations in the evidence, and evaluates emerging approaches. Methods: In this structured narrative review, PubMed/MEDLINE, Scopus, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched for relevant records published through 15 August 2026. Priority was given to randomized trials, prospective cohorts, systematic reviews and meta-analyses, large registry studies, and international guidelines. Results: For atypical endometrial hyperplasia/endometrial intraepithelial neoplasia and carefully selected grade 1, stage IA endometrioid carcinoma without myometrial invasion, progestin-based treatment achieves complete response in approximately three-quarters of patients, although recurrence affects about one-third of responders. Hysteroscopic resection followed by progestin therapy may improve response and recurrence outcomes in focal disease, but comparative evidence is heterogeneous and largely non-randomized. In ovarian tumors, fertility-sparing surgery is standard for borderline tumors without invasive implants and malignant germ cell tumors and may be considered for selected early-stage epithelial and sex cord–stromal tumors after histotype-specific staging. Oocyte and embryo cryopreservation are established options when treatment threatens ovarian reserve; ovarian tissue cryopreservation and in vitro maturation have more selective indications. Molecular classification may refine counseling, whereas circulating tumor DNA, artificial-ovary platforms, in vitro follicle development, and uterus transplantation remain investigational. Conclusions: Fertility-preserving management can be oncologically acceptable with rigorous selection, multidisciplinary counseling, protocolized surveillance, and timely definitive treatment when indicated. Prospective, molecularly stratified studies with standardized oncological and reproductive outcomes are needed.

Authors

Institutions

Publication Details

Journal
Reproductive Medicine
Published
2026-11-19
DOI
https://doi.org/10.3390/reprodmed7040070
Primary Topic
Reproductive Biology and Fertility
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Fertility Preservation in Endometrial and Ovarian Cancer: Evidence, Challenges and Emerging Approaches

Marco Crosa, Francesco Paolo Rosato, Simone Ferrero, Fabio Barra et al.
Reproductive Medicine
Reproductive Biology and Fertility
article

Fertility Preservation in Endometrial and Ovarian Cancer: Evidence, Challenges and Emerging Approaches

Marco Crosa, Francesco Paolo Rosato, Simone Ferrero, Fabio Barra, Silvia Ottonello, Margherita Tortello
article en

Abstract

Fertility preservation is increasingly relevant for reproductive-aged patients with endometrial or ovarian cancer, but oncological safety must remain the primary objective. This review summarizes current oncological and reproductive outcomes, identifies limitations in the evidence, and evaluates emerging approaches. Methods: In this structured narrative review, PubMed/MEDLINE, Scopus, Embase, the Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched for relevant records published through 15 August 2026. Priority was given to randomized trials, prospective cohorts, systematic reviews and meta-analyses, large registry studies, and international guidelines. Results: For atypical endometrial hyperplasia/endometrial intraepithelial neoplasia and carefully selected grade 1, stage IA endometrioid carcinoma without myometrial invasion, progestin-based treatment achieves complete response in approximately three-quarters of patients, although recurrence affects about one-third of responders. Hysteroscopic resection followed by progestin therapy may improve response and recurrence outcomes in focal disease, but comparative evidence is heterogeneous and largely non-randomized. In ovarian tumors, fertility-sparing surgery is standard for borderline tumors without invasive implants and malignant germ cell tumors and may be considered for selected early-stage epithelial and sex cord–stromal tumors after histotype-specific staging. Oocyte and embryo cryopreservation are established options when treatment threatens ovarian reserve; ovarian tissue cryopreservation and in vitro maturation have more selective indications. Molecular classification may refine counseling, whereas circulating tumor DNA, artificial-ovary platforms, in vitro follicle development, and uterus transplantation remain investigational. Conclusions: Fertility-preserving management can be oncologically acceptable with rigorous selection, multidisciplinary counseling, protocolized surveillance, and timely definitive treatment when indicated. Prospective, molecularly stratified studies with standardized oncological and reproductive outcomes are needed.

Reproductive MedicineVol. 7(4)
Ospedale Policlinico San Martino (IT), IRCCS Azienda Ospedaliera Metropolitana (IT), University of Genoa (IT)
Reproductive Biology and Fertility
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon